Activation of AP-1 and increased synthesis of MMP-9 in the rabbit retina induced by lipid hydroperoxide

Current Eye Research

Volumn 31, Issue 4, 2006, Pages 337-346

  Iwai, Shinichi ^a,b   Aljada, Ahmad ^c   Higa, Akira ^a,b   Nakanishi Ueda, Takako ^b   Fukuda, Shohei ^b   Kamegawa, Maki ^b   Iwabuchi, Shigehiro ^b   Ueda, Toshihiko ^b   Caballero, Sergio ^d   Browne, Richard ^c   Afzal, Aqeela ^a   Grant, Maria ^d   Yasuhara, Hajime ^b   Koide, Ryohei ^b   Oguchi, Katsuji ^b   Dandona, Paresh ^c   Armstrong, Donald ^a,b,c  

^a University of Florida College of Veterinary Medicine   (United States)

^b SHOWA UNIVERSITY   (Japan)

^c UNIVERSITY AT BUFFALO   (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Activator protein 1; Lipid hydroperoxide; Matrix metalloproteinases; Neovascularization; Retina

Indexed keywords

GELATINASE B; LINOLEIC ACID; LIPID HYDROPEROXIDE; MATRIX METALLOPROTEINASE; MESSENGER RNA; TRANSCRIPTION FACTOR AP 1;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; MALE; NONHUMAN; PHOTORECEPTOR; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RABBIT; RETINA NEOVASCULARIZATION; SYNTHESIS; VITREOUS BODY;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ELECTROPHORETIC MOBILITY SHIFT ASSAY; INJECTIONS; LINOLEIC ACIDS; LIPID PEROXIDES; MALE; MATRIX METALLOPROTEINASE 9; RABBITS; RETINA; RETINAL NEOVASCULARIZATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION FACTOR AP-1; VITREOUS BODY;

EID: 33645794017     PISSN: 02713683     EISSN: None     Source Type: Journal    
DOI: 10.1080/02713680600577780     Document Type: Article

References (69)

1. Folkman J, Shing Y. Angiogenesis. J Biol Chem. 1992;267:10931-10934.
2. Hockel M, Schlenger K, Doctrow S, et al. Therapeutic angiogenesis. Arch Surg. 1993;128:423-429.
3. Davis MD. Proliferative diabetic retinopathy. In: Ryan SJ. Retina. St. Louis: C. V. Mosby; 1994;1319-1360.
4. Glaser BM, Lemor M. Pathobiology of proliferative vitreoretinopathy. In Retina (Ryan, S. J., Ed) C. V. Mosby: St. Louis. 1994;2249-2264.
5. Elman MJ, Fine SL. Exudative age-related macular degeneration. In Retina (Ryan, S. J., Ed) C. V. Mosby: St. Louis. 1994;1103-1142.
6. De La Paz M, nderson RE. Region and age-dependent variation in susceptibility of the human retina to lipid peroxidation. Invest Ophthalmol Vis Sci. 1992;33:3497-3499.
7. Spaide RF, Ho-Spaide WC, Browne RW, Armstrong D. Characterization of peroxidized lipids in Bruch's membrane. Retina 1999;19(2):141-147.
8. Armstrong D, Abdella N, Salman A, et al. Relationship of lipid peroxides to diabetic complications. Comparison with conventional laboratory tests. J Diabetes Comp. 1992;6(2):116-122.
9. Armstrong D, Ueda T, Ueda T, et al. Lipid hydoroperoxide stimulates retinal neovascularization in rabbit retina through expression of tumor necrosis factor-α, vascular endothelial growth factor and platelet-derived growth factor. Angiogenesis. 1998;2:93-104.
10. Ueda T, Ueda T, Fukuda S, et al. Lipid hydroperoxide-induced tumor necrosis factor (TNF)-α, vascular endothelial growth factor and neovascularization in the rabbit cornea: Effect of TNF inhibition. Angiogenesis. 1997;1:174-184.
11. Tamai K, Spaide RF, Ellis EA, et al. Lipid hydroperoxide stimulates subretinal choroidal neovascularization in the rabbit. Exp Eye Res. 2002;74(2):301-308.
12. Armstrong D, Hiramitsu T, Gutteridge J, Nilssen SE. Studies on experimentally induced retinal degeneration. 1. Effect of lipid peroxides on electroretinographic activity in albino rabbits. Exp Eye Res. 1982;35:157-171.
13. Armstrong D, Ueda TO, et al. Dose dependent mechanisms of lipid hydroperoxide induced retinal pathology. In Pathophysiology of Lipid Peroxides and Related Free Radicals, ed by Yagi, K., Japan Sci Soc Press, Tokyo and S. Karger AG, Basel, 1998;57-76.
14. Rundhaug JE. Matrix metalloproteinases and angiogenesis. J Cell Mol Med. 2005;9(2):267-285.
15. Kon CH, Occleston NL, Charteris D, et al. A prospective study of matrix metalloproteinases in proliferative vitreoretinapathy. Invest Ophthalmol. Vis Sci. 1998;39:1524-1529.
16. Kvanta A, Sarman S, Fagerholm P, et al. Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization. Exp Eye Res. 2000;70:419-428.
17. Plantner JJ, Jiang C, Smine A. Increase in interphotoreceptor matrix gelatinase A (MMP-2) associated with age-related macular degeneration. Exp Eye Res. 1998;67:637-645.
18. Guo Li, Hussain AA, Limb A, Marshall J. Age-dependent variation in metalloproteinase activity of isolated human Bruch's membrane and choroid. Invest Ophthalmol Vis Sci. 1999;40:2676-2682.
19. Murphy G, Ward R, Hembry RM, et al. Characterization of gelatinase from pig polymorphonuclear leucocytes. A metalloproteinase resembling tumour type IV collagenase. Biochem J. 1989;258(2):463-472.
20. Vu, TH, Werb, Z. Matrix metalloproteinases: Effectors of development and normal physiology. Genes Dev. 2000;14:2123-2133.
21. Leppert D, Lindberg RL, Kappos L, Leib SL. Matrix metalloproteinases: Multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. Brain Res Brain Res Rev. 2001;36(2-3):249-257.
22. Benbow U, Brinckerhoff CE. The AP-1 site and MMP gene regulation: What is all the fuss about? Matrix Biol. 1997;15(8-9):519-526.
23. Fei J, Viedt C, Soto U, et al. Endothelin-1 and smooth muscle cells: Induction of jun amino-terminal kinase through an oxygen radical-sensitive mechanism. Arterioscler Thromb Vasc Biol. 2000;20:1244-1249.
24. Dabrowski A, Boguslowicz C, Dabrowska M, et al. Reactive oxygen species activate mitogen-activated protein kinases in pancreatic acinar cells. Pancreas. 2000;21(4):376-384.
25. Virag L. Structure and function of poly (ADP-ribose) polymerase-1: Role in oxidative stress-related pathologies. Curr Vasc Pharmacol. 2005;3(3):209-214.
26. Virag L, Szabo C. The therapeutic potential of poly (ADP-ribose) polymerase inhibitors. Pharmacol Rev. 2002;54(3):375-429.
27. Armstrong D, Browne RW. Synthesis of lipid and cholesterol hydroperoxide standards. In Free Radical and Antioxidant Protocols. Metheods in Molecular Biology, vol. 108. ed by Armstrong, D. Humana Press, Totowa, NJ. 1998;139-45.
28. Browne RW, Armstrong D. Simultaneous determination of polyunsaturated fatty acids and corresponding monohydroperoxy and monohydroxy peroxidation products by HPLC. In: Armstrong D. Oxidative Stress Biomarkers and Antioxidant Protocols. Metheods in Mololerular Biology, vol. 186. Totowa, NJ: Humana Press, 2002;13-20.
29. Sasaki K, Hattori T, Fujisawa T, et al. Nitric oxide mediates interleukin-1-induced gene expression of matrix metalloproteinases and basic fibroblast growth factor in cultured rabbit articular chondrocytes. J. Biochem. 1998;123(3):431-439.
30. Grant MB, Caballero S, Tarnuzzer RW, et al. Matrix metalloproteinase expression in human retinal microvascular cells. Diabetes. 1998;47:1311-1317.
31. Friedrichs B, Toborek M, Hennig B, et al. 13-HPODE and 13-HODE modulate cytokine-induced expression of endothelial cell adhesion molecules differently. Biofactors. 1999;9(1):61-72.
32. Nagy L, Tontonoz P, Alvarez JGA, et al. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ. Cell. 1998;93:229-240.
33. Armstrong D, Browne RW. The analysis of free radicals, lipid peroxides, antioxidant enzymes and compounds related to oxidative stress as applied to the clinical chemistry laboratory. Adv Exp Med Biol. 1994;366:43-58.
34. Leonarduzzi G, Arkan MC, Başaǧa H, et al. Lipid oxidation products in cell signaling. Free Radic Biol Med. 2000;28(9):1370-1378.
35. Moses MA, Sudhalter J, Langer R. Identification of an inhibitor of neovascularization from cartilage. Science. 1990;248:1408-1410.
36. Klagsbrun M, Moses MA. Molecular angiogenesis. Chem Biol. 1999;6:R217-224.
37. Iruela-Arispe ML, Dvorak HF. Angiogenesis: A dynamic balance of stimulators and inhibitors. Thromb Haemost. 1997;78(1):672-677.
38. Burdon RH. Superoxide and hydrogen peroxide in relation to mammalian cell proliferation. Free Radic Biol Med. 1995;18(4):775-794.
39. Guha M, Bai W, Nadler JL, Natarajan R. Molecular mechanisms of tumor necrosis factor alpha gene expression in monocytic cells via hyperglycemia-induced oxidant stress-dependent and -independent pathways. J Biol Chem. 2000;275(23):17728-17739.
40. Lee YW, Hennig B, Fiala M, et al. Cocaine activates redox-regulated transcription factors and induces TNF-alpha expression in human brain endothelial cells. Brain Res. 2001;920(1-2):125-133.
41. Rosenfeld ME. Inflammation, lipids, and free radicals: Lessons learned from the atherogenic process. Semin Reprod Endocrinol. 1998;16(4):249-261.
42. Majka S, McGuire PG, Das A. Regulation of matrix metalloproteinase expression by tumor necrosis factor in a murine model of retinal neovascularization. Invest Ophthalmol Vis Sci. 2002;43(1):260-266.
43. Alikacem N, Yoshizawa T, Nelson KD, Wilson CA. Quantitative MR imaging study of intravitreal sustained release of VEGF in rabbit. Invest Ophthalmol Vis Sci. 2000;41:1561-1569.
44. Lin CW, Georgescu HI, Evans CH. The role of AP-1 in matrix metalloproteinase gene expression. Agents Actions. 1993;39:C215-218.
45. Gum R, Lengyel E, Juarez J, et al. Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences. J Biol Chem. 1996;271:10672-10680.
46. Himelstein BP, Lee EJ, Sato H, et al. Transcriptional activation of the matrix metalloproteinase-9 gene in an H-ras and v-myc transformed rat embryo cell line. Oncogene. 1997;14:1995-1998.
47. Bond M, Fabunmi RP, Baker AH, Newby AC. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: An absolute requirement for transcription factor NF-κB. FEBS Lett. 1998;435:29-34.
48. Troussard AA, Costello P, Yoganathan TN, et al. The integrin linked kinase (ILK) induces an invasive phenotype via AP-1 transcription factor-dependent upregulation of matrix metalloproteinase 9(MMP-9). Oncogene. 2000;19:5444-5452.
49. Fariss RN, Apte SS, Luthert PJ, et al. Accumulation of tissue inhibitor of metalloproteinases-3 in human eyes with Sorsby's fundus dystrophy or retinitis pigmentosa. Br J Ophthalmol. 1998;82(11):1329-1334.
50. Sang QX. Complex role of matrix metalloproteinases in angiogenesis. Cell Res. 1998;8(3):171-177.
51. Ikenaka Y, Yoshiji H, Kuriyama S, et al. Tissue inhibitor of metalloproteinases-1 (TIMP-1) inhibits tumor growth and angiogenesis in the TIMP-1 transgenic mouse model. Int J Cancer. 2003;105(3):340-346.
52. Huhtala P, Chow LT, Tryggvason K. Structure of the human type IV collagenase gene. J Biol Chem. 1990;265(19):11077-11082.
53. Frisch SM, Morisaki JH. Positive and negative transcriptional elements of the human type IV collagenase gene. Mol Cell Biol. 1990;10(12):6524-6532.
54. Harendza S, Pollock AS, Mertens PR, Lovett DH. Tissue-specific enhancer-promoter interactions regulate high level constitutive expression of matrix metalloproteinase 2 by glomerular mesangial cells. J Biol Chem. 1995;270(32):18786-18796.
55. Tomasek JJ, Halliday NL, Updike DL, et al. Gelatinase A activation is regulated by the organization of the polymerized actin cytoskeleton. J Biol Chem. 1997;272:7482-7487.
56. Strongin AY, Collier I, Bannikov G, et al. Mechanism of cell surface activation of 72-kDa type IV collagenase. J Biol Chem. 1995;270:5331-5338.
57. Laderoute KR, Calaoagan JM, Knapp AM, et al. C-jun cooperate with SV40 T-antigen to sustain MMP-2 expression in immortalized cells. Biochem Biophys Res Commun. 2001;284(5):1134-1139.
58. Plantner JJ, Smine A, Quinn TA. (1998b). Matrix metalloproteinase and metalloproteinase inhibitors in human interphotoreceptor matrix and vitreous. Curr Eye Res. 17, 132-40.
59. De La Paz MA, Itoh Y, Toth CA, Nagase H. Matrix metalloproteinases and their inhibitors in human vitreous. Invest Ophthalmol Vis Sci. 1998;39:1256-1260.
60. Behzadian MA, Wang X, Windsor LJ, et al. TGF-b increases retinal endothelial cell permeability by increasing MMP-9: Possible role of glial cells in endothelial barrier function. Invest Ophthalmol Vis Sci. 2001;42:853-859.
61. Zhang X, Sakamoto T, Hata Y, et al. Expression of matrix metalloproteinases and their inhibitors in experimental retinal ischemia-reperfusion injury in rats. Exp Eye Res. 2002;74(5):577-584.
62. Padgett LC, Lui G, Werb Z, LaVail MM. Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 in retinal pigment epithelium and interphotoreceptor matrix: Vectorial secretion and regulation. Exp Eye Res. 1997;64:927-938.
63. Lengyel E, Schmalfeldt B, Konik E, et al. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecol Oncol. 2001;82:291-298.
64. r 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res. 1993;53:140-146.
65. Yu Q, Stamenkovic I. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev. 1999;13:35-48.
66. Uemura S, Matsushita H, Li W, et al. Tsao PS. Diabetes mellitus enhances vascular matrix metalloproteinase activity role of oxidative stress. Circ Res. 2001;88:1291-1298.
67. Sarman S, van der Ploeg I, Seregard S, Kvanta A. Retinal vascular development and pathologic retinal angiogenesis are not impaired in matrix metalloproteinase-2 deficient mice. Curr Eye Res. 2005;30(4):259-267.
68. Kosano H, Okano T, Katsura Y, et al. ProMMP-9 (92 kDa gelatinase) in vitreous fluid of patients with proliferative diabetic retinopathy. Life Sci. 1999;64:2307-2315.
69. Lambert V, Munaut C, Jost M, et al. Matrix metalloproteinase-9 contributes to choroidal neovascularization. Am J Pathol. 2002;161(4):1247-1253.